Get the Stockscreener App
137.64
0.98%
1.34
After Hours:
137.64
Jazz Pharmaceuticals Plc stock is traded at $137.64, with a volume of 524.52K.
It is up +0.98% in the last 24 hours and up +4.43% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$136.30
Open:
$136.78
24h Volume:
524.52K
Relative Volume:
0.70
Market Cap:
$8.35B
Revenue:
$4.09B
Net Income/Loss:
$-404.84M
P/E Ratio:
-20.40
EPS:
-6.7469
Net Cash Flow:
$1.24B
1W Performance:
-0.64%
1M Performance:
+4.43%
6M Performance:
+17.68%
1Y Performance:
+25.09%
1-Day Range:
$135.63
$138.31
1-Week Range:
$133.45
$140.00
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
137.64 | 8.27B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
How Jazz Pharmaceuticals plc (J7Z) stock performs in easing cyclesPortfolio Risk Report & AI Driven Stock Movement Reports - newser.com
What Jazz Pharmaceuticals (JAZZ)'s Cross-Licensing Settlement With Avadel Means For Shareholder Value - Yahoo! Finance UK
Why Jazz Pharmaceuticals plc stock is trending among retail tradersJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Can Jazz Pharmaceuticals plc stock hit record highs againPortfolio Update Summary & Smart Investment Allocation Insights - newser.com
Assetmark Inc. Purchases 82,275 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Are Jazz Pharmaceuticals Shares Still Attractive After a 25% Climb and New Pipeline Developments? - simplywall.st
Why Jazz Pharmaceuticals plc (J7Z) stock could be next leaderJuly 2025 Closing Moves & Precise Buy Zone Tips - newser.com
Multi factor analysis applied to Jazz Pharmaceuticals plc2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
How Jazz Pharmaceuticals plc stock trades during market volatilityJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Kovack Advisors Inc. - MarketBeat
Statistical indicators supporting Jazz Pharmaceuticals plc’s strengthJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
Impact Partnership Wealth LLC Takes Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
When is the best time to exit Jazz Pharmaceuticals plcJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
How Investors May Respond To Jazz Pharmaceuticals (JAZZ) Settling Global LUMRYZ Patent Dispute with Avadel - simplywall.st
Best data tools to analyze Jazz Pharmaceuticals plc stock2025 Market Overview & Reliable Volume Spike Alerts - newser.com
Is Jazz Pharmaceuticals plc (J7Z) stock a momentum leaderTrade Ideas & Long-Term Investment Growth Plans - newser.com
How strong is Jazz Pharmaceuticals plc stock revenue growthTrade Risk Assessment & Fast Gain Stock Tips - newser.com
Why Jazz Pharmaceuticals plc stock is seen as undervalued2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Jazz Pharmaceuticals plc stock outlook for YEARJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
Is Jazz Pharmaceuticals plc stock a buy before product launchesJuly 2025 Summary & Daily Technical Forecast Reports - newser.com
Jazz Pharmaceuticals plc (JAZZ) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Jazz Pharmaceuticals (JAZZ) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will Jazz Pharmaceuticals plc stock see PE expansionWeekly Profit Recap & High Win Rate Trade Tips - newser.com
Jazz Pharmaceuticals plc (JAZZ) Stock forecasts - Yahoo! Finance UK
What Technical Volume Patterns Indicate for Hinduja Global Solutions LimitedLong-Term Investment Plans & High Yield Investment Portfolio - earlytimes.in
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance
JAZZ (Jazz Pharmaceuticals) Forward Rate of Return (Yacktma - GuruFocus
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline - Yahoo Finance
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors - The AI Journal
Jazz Pharmaceuticals Announces Board Changes - TradingView
JAZZ appoints Dr. Ted Love to Board, sets term to 2027 AGM - Stock Titan
Jazz Pharmaceuticals plc Announces Board Changes, Effective December 1, 2025 - MarketScreener
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $199.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):